Four years after being taken private, Parexel has been sold again, with Goldman Sachs' private equity arm and EQT paying $8.5 billion to claim ownership of the contract research organisatio
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
